Jubilant Ingrevia Q1 FY27 Revenue Jumps 25% to ₹1,300 Cr, EBITDA Up 36%
Jubilant Ingrevia reported Q1 FY27 revenue of ₹1,300 crore (up 25% YoY) and EBITDA of ₹209 crore (up 36% YoY). PAT grew 41% YoY to ₹106 crore, and EPS rose to ₹6.7. Specialty Chemicals revenue was ₹533 crore, Nutrition & Health Solutions ₹243 crore, and Chemical Intermediates ₹524 crore. The company expects sequential revenue and EBITDA improvement.
The strong financial performance and positive outlook are material to investors and indicate potential for continued growth.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with positive commentary from management about future outlook and market conditions.
Jubilant Ingrevia Limited announced strong financial results for the first quarter ended June 30, 2026 (Q1 FY27), with total revenue reaching ₹1,300 crore, a significant 25% year-on-year (YoY) increase. The company's EBITDA also saw robust growth, rising by 36% YoY to ₹209 crore. Profit After Tax (PAT) after exceptional items stood at ₹106 crore, marking a 41% YoY increase. The Earnings Per Share (EPS) grew by 41% YoY to ₹6.7.
The Specialty Chemicals segment reported revenue of ₹533 crore, an 11% YoY increase, with EBITDA at ₹139 crore and margins at 26%. The Nutrition and Health Solutions segment delivered strong growth, with revenue up 36% YoY to ₹243 crore and EBITDA increasing by 45% YoY to ₹36 crore, with improved margins of 15%. The Chemical Intermediates segment witnessed a significant rebound, with revenue growing 38% YoY to ₹524 crore and EBITDA surging 240% YoY to ₹57 crore, with margins improving to 11%.
Management highlighted the company's strong start to FY27, driven by healthy financial performance, resilient demand across industries, and disciplined execution. The company anticipates sequential improvement in revenue and EBITDA over the coming quarters, with growth expected to be led by Specialty Chemicals and Nutrition, alongside a recovery in Acetyls. The new Multi-Purpose Plant is on track for commissioning by the end of the current calendar year.
The company also achieved several operational and ESG milestones, including progress on its Pinnacle journey, lean savings targets, and advancements in its Supernova program. Jubilant Ingrevia was recognized as a Great Place to Work and received safety awards for its manufacturing facilities. The integration of Remidex Pharma post-acquisition is progressing well, and the company is actively evaluating new growth opportunities.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.